<DOC>
	<DOCNO>NCT01402661</DOCNO>
	<brief_summary>The Corrona Data Collection Program study design systematically collect document use pattern , effectiveness , safety DMARDs ( Disease Modifying Anti-Rheumatic Drugs ) , biologic agent treatment currently use management Rheumatoid Arthritis ( RA ) , Undifferentiated Arthritis ( UA ) , Psoriatic Arthritis ( PsA ) , rheumatic disease . Data collect Corrona Data Collection Program maintain comprehensive database ( Corrona Database ) , use purpose related clinical , outcomes , market research . Participating physicians access information participate patient , may use information purpose research provide patient care . It anticipate study data may help improve quality information upon clinical decision base .</brief_summary>
	<brief_title>The Corrona RA Data Collection Program</brief_title>
	<detailed_description>The Corrona Data Collection Program represent novel advance collecting , analyze , report real-time data trend issue . Information gather Corrona Data Collection Program maintain comprehensive database ( Corrona Database ) . The Corrona Organization provide participate site access technology enable interact manipulate data maintain Corrona Database patient population . The Corrona Organization use Corrona Database purpose related clinical , marketing , outcomes research . Significantly , Corrona Organization intend conduct novel clinical trial rheumatology . In addition , Corrona Organization provide report regard information contain Corrona Database fee select industry subscriber allow direct access Corrona Database . Rather , permit submit research query Corrona Organization execute Corrona biostatisticians generate appropriate response query . Physicians subject complete Corrona Data Collection Program Questionnaires ( see Appendix B ) approximately every four month ( RA ) six month ( PsA UA ) . During course regularly-scheduled office visit , physician performs assessment mandate Corrona Data Collection Program Physician Questionnaires record pertinent data . Results certain laboratory test include , mandate , Questionnaires . Subjects ask complete Data Collection Program Questionnaires design capture information range general demographic experience prescription drug use overall global assessment disease . During regularly-scheduled physician office visit , anticipated spend approximately five ten minute complete Questionnaires . Neither Questionnaires complete physician Questionnaires complete subject contain subject 's name , address , telephone number , email address , social security number . Patients enrol Corrona Data Collection Program regularly-scheduled office visit . Upon enrollment , physicians complete set Enrollment Questionnaires , include 28 joint count ( see Appendix C ) New Biologic Start ( NBS ) Questionnaire appropriate . Subjects also complete Corrona Data Collection Program Enrollment Questionnaire along Health Assessment EQ5D In event biologic new start biologic switch RA patient , physician complete NBS Questionnaire , Appendix A . Appendix B complete physician subject cooperatively next Corrona visit . If Appendix B Questionnaire complete visit next subsequent visit , set Appendices null void . In event subject initiate A NEW BIOLOGIC discontinues biologic visit , Appendices A ( FOR THE NEW BIOLOGIC ) B ( FOR THE BIOLOGIC BEING DISCONTINUED ) complete visit . Data collect subject long consent remain study . Any adverse event spontaneously volunteer subject discover result general questioning investigator record Provider Follow-up Questionnaire visit .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female patient , least 18 year age Able willing provide write consent participation Meeting one follow diagnostic criterion RA : Diagnosis RA 1987 ARA 2010 ACR/EULAR criterion approve biologic small molecule medication Diagnosed RA within last 12 month meet 1987 ARA 2010 ACR/EULAR RA diagnostic criterion regardless RA treatment regimen Subjects previously enrol Corrona Treat Target trial , regardless treatment regimen time enrollment RA registry The subject unable unwilling provide inform consent participate registry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>psoriatic arthritis</keyword>
	<keyword>disease registry</keyword>
</DOC>